Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.

Burford A, Little SE, Jury A, Popov S, Laxton R, Doey L, Al-Sarraj S, Jürgensmeier JM, Jones C.

PLoS One. 2013 Aug 21;8(8):e71777. doi: 10.1371/journal.pone.0071777. eCollection 2013.

2.

Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.

Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN.

J Pathol. 2005 Oct;207(2):224-31.

PMID:
16021678
3.

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.

Puputti M, Tynninen O, Sihto H, Blom T, Mäenpää H, Isola J, Paetau A, Joensuu H, Nupponen NN.

Mol Cancer Res. 2006 Dec;4(12):927-34.

4.

Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.

Nobusawa S, Stawski R, Kim YH, Nakazato Y, Ohgaki H.

Neuropathology. 2011 Dec;31(6):583-8. doi: 10.1111/j.1440-1789.2011.01204.x. Epub 2011 Mar 7.

PMID:
21382095
5.

The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.

Jansson S, Bendahl PO, Grabau DA, Falck AK, Fernö M, Aaltonen K, Rydén L.

PLoS One. 2014 Jul 15;9(7):e102176. doi: 10.1371/journal.pone.0102176. eCollection 2014.

6.

Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.

Johansson I, Aaltonen KE, Ebbesson A, Grabau D, Wigerup C, Hedenfalk I, Rydén L.

Genes Chromosomes Cancer. 2012 Apr;51(4):375-83. doi: 10.1002/gcc.21922. Epub 2011 Dec 14.

PMID:
22170730
7.

High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.

Knösel T, Chen Y, Altendorf-Hofmann A, Danielczok C, Freesmeyer M, Settmacher U, Wurst C, Schulz S, Yang LL, Petersen I.

J Cancer Res Clin Oncol. 2012 Mar;138(3):397-403. doi: 10.1007/s00432-011-1107-9. Epub 2011 Dec 8.

PMID:
22160160
8.

Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.

Chen D, Persson A, Sun Y, Salford LG, Nord DG, Englund E, Jiang T, Fan X.

PLoS One. 2013 Apr 22;8(4):e61556. doi: 10.1371/journal.pone.0061556. Print 2013.

9.

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.

Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T, Brennan CW.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6. doi: 10.1073/pnas.1114033109. Epub 2012 Feb 8.

10.

Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.

Ruano Y, Mollejo M, Ribalta T, Fiaño C, Camacho FI, Gómez E, de Lope AR, Hernández-Moneo JL, Martínez P, Meléndez B.

Mol Cancer. 2006 Sep 26;5:39.

11.

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.

Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN, Butzow R.

Br J Cancer. 2004 Dec 13;91(12):2048-55.

12.

KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN, Joensuu H.

J Clin Oncol. 2005 Jan 1;23(1):49-57. Epub 2004 Nov 15.

13.

Amplification of chromosomal segment 4q12 in non-small cell lung cancer.

Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M.

Cancer Biol Ther. 2009 Nov;8(21):2042-50. Epub 2009 Nov 7.

14.

Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study.

Niini T, López-Guerrero JA, Ninomiya S, Guled M, Hattinger CM, Michelacci F, Böhling T, Llombart-Bosch A, Picci P, Serra M, Knuutila S.

Genes Chromosomes Cancer. 2010 Feb;49(2):132-43. doi: 10.1002/gcc.20727.

PMID:
19862822
15.

Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.

Blom T, Roselli A, Häyry V, Tynninen O, Wartiovaara K, Korja M, Nordfors K, Haapasalo H, Nupponen NN.

J Neurooncol. 2010 Apr;97(2):217-24. doi: 10.1007/s11060-009-0014-2. Epub 2009 Sep 25.

PMID:
19779861
16.

The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

Zietsch J, Ziegenhagen N, Heppner FL, Reuss D, von Deimling A, Holtkamp N.

PLoS One. 2010 Jul 29;5(7):e11858. doi: 10.1371/journal.pone.0011858.

17.

Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.

Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, Gronchi A, Pastorino U, Pierotti MA, Pilotti S.

J Pathol. 2007 Jun;212(2):227-35.

PMID:
17471466
18.

KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs).

Tabone S, Théou N, Wozniak A, Saffroy R, Deville L, Julié C, Callard P, Lavergne-Slove A, Debiec-Rychter M, Lemoine A, Emile JF.

Biochim Biophys Acta. 2005 Jun 30;1741(1-2):165-72. Epub 2005 Apr 13.

19.

PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.

Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, Martinez-Lage M, Robinson AE, Yong WH, Cloughesy T, Lai A, Phillips HS, Marshall R, Mueller S, Haas-Kogan DA, Molinaro AM, Perry A.

Brain Pathol. 2013 Sep;23(5):565-73. doi: 10.1111/bpa.12043. Epub 2013 Mar 18.

20.

Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors.

Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, Gronchi A, Casali PG, Pierotti MA, Tamborini E, Pilotti S.

Anal Quant Cytol Histol. 2010 Aug;32(4):225-33.

PMID:
21434524
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk